Bipartite binding of the N terminus of Skp2 to cyclin A.


Journal

Structure (London, England : 1993)
ISSN: 1878-4186
Titre abrégé: Structure
Pays: United States
ID NLM: 101087697

Informations de publication

Date de publication:
02 09 2021
Historique:
received: 24 02 2021
revised: 06 04 2021
accepted: 23 04 2021
pubmed: 15 5 2021
medline: 17 3 2022
entrez: 14 5 2021
Statut: ppublish

Résumé

Skp2 and cyclin A are cell-cycle regulators that control the activity of CDK2. Cyclin A acts as an activator and substrate recruitment factor of CDK2, while Skp2 mediates the ubiquitination and subsequent destruction of the CDK inhibitor protein p27. The N terminus of Skp2 can interact directly with cyclin A but is not required for p27 ubiquitination. To gain insight into this poorly understood interaction, we have solved the 3.2 Å X-ray crystal structure of the N terminus of Skp2 bound to cyclin A. The structure reveals a bipartite mode of interaction with two motifs in Skp2 recognizing two discrete surfaces on cyclin A. The uncovered binding mechanism allows for a rationalization of the inhibitory effect of Skp2 on CDK2-cyclin A kinase activity toward the RxL motif containing substrates and raises the possibility that other intermolecular regulators and substrates may use similar non-canonical modes of interaction for cyclin targeting.

Identifiants

pubmed: 33989513
pii: S0969-2126(21)00127-1
doi: 10.1016/j.str.2021.04.011
pmc: PMC8419023
mid: NIHMS1705908
pii:
doi:

Substances chimiques

Cyclin A 0
S-Phase Kinase-Associated Proteins 0
SKP2 protein, human 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

975-988.e5

Subventions

Organisme : NIGMS NIH HHS
ID : P30 GM124165
Pays : United States
Organisme : CIHR
ID : FDN-143277
Pays : Canada

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests F.S. is a founder and consultant of Repare Therapeutics.

Références

Nature. 2000 Nov 16;408(6810):381-6
pubmed: 11099048
Nat Commun. 2019 Apr 11;10(1):1676
pubmed: 30976006
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Nat Cell Biol. 1999 Nov;1(7):438-43
pubmed: 10559988
Annu Rev Biochem. 2012;81:203-29
pubmed: 22524316
Dev Cell. 2018 Jun 4;45(5):637-650.e7
pubmed: 29870721
Nat Cell Biol. 2001 Mar;3(3):321-4
pubmed: 11231585
Nat Struct Mol Biol. 2004 Apr;11(4):358-64
pubmed: 15024385
Cell. 1996 Jul 26;86(2):263-74
pubmed: 8706131
Biochemistry. 2002 Dec 31;41(52):15625-34
pubmed: 12501191
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
Methods. 2011 Sep;55(1):94-106
pubmed: 21821126
Nature. 1995 Jul 27;376(6538):313-20
pubmed: 7630397
Cell Rep. 2016 Apr 19;15(3):510-518
pubmed: 27068477
Mol Syst Biol. 2011 Oct 11;7:539
pubmed: 21988835
Mol Cell Biol. 1999 Jan;19(1):635-45
pubmed: 9858587
Nature. 2004 Mar 11;428(6979):190-3
pubmed: 15014502
Science. 2019 Dec 13;366(6471):
pubmed: 31831640
Cell Cycle. 2007 Jun 1;6(11):1350-9
pubmed: 17495531
Cell. 2012 Jul 6;150(1):179-93
pubmed: 22770219
Nat Cell Biol. 1999 Aug;1(4):207-14
pubmed: 10559918
Curr Biol. 2015 Feb 2;25(3):316-325
pubmed: 25619768
Mol Cell. 2004 Oct 8;16(1):47-58
pubmed: 15469821
EMBO J. 2021 Jan 15;40(2):e105839
pubmed: 33210757
J Mol Biol. 2021 Mar 5;433(5):166795
pubmed: 33422522
Genes Dev. 1999 May 1;13(9):1181-9
pubmed: 10323868
Cell. 1997 Oct 17;91(2):209-19
pubmed: 9346238
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Nat Cell Biol. 1999 Aug;1(4):193-9
pubmed: 10559916
Cell. 1996 Mar 22;84(6):863-74
pubmed: 8601310
Mol Cell Biol. 1996 Sep;16(9):4673-82
pubmed: 8756624
Mol Cell Biol. 2001 Aug;21(15):4868-74
pubmed: 11438644
Curr Biol. 2020 Nov 16;30(22):4454-4466.e5
pubmed: 32976810
Bioinformatics. 2009 May 1;25(9):1189-91
pubmed: 19151095
Nat Rev Mol Cell Biol. 2008 Nov;9(11):910-6
pubmed: 18813291
J Biol Chem. 2006 Aug 18;281(33):24058-69
pubmed: 16774918
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
Elife. 2013 Sep 10;2:e01456
pubmed: 24040512
Cell. 1995 Sep 22;82(6):915-25
pubmed: 7553852
Nature. 2004 Mar 11;428(6979):194-8
pubmed: 15014503
Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10453-8
pubmed: 9724724
EMBO J. 1997 Sep 1;16(17):5334-44
pubmed: 9311993
Mol Cell Biol. 1996 Dec;16(12):6623-33
pubmed: 8943316
Curr Biol. 1999 Jun 17;9(12):661-4
pubmed: 10375532
Nat Cell Biol. 2009 Apr;11(4):397-408
pubmed: 19270695
Cell. 1997 Oct 17;91(2):221-30
pubmed: 9346239
Mol Cell. 2001 Mar;7(3):639-50
pubmed: 11463388
Nature. 1996 Jul 25;382(6589):325-31
pubmed: 8684460
Cell Rep. 2020 Jun 16;31(11):107757
pubmed: 32553169

Auteurs

Susan Kelso (S)

Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5G 1X5, Canada; Department of Molecular Genetics, University of Toronto, ON M5S 1A8, Canada.

Stephen Orlicky (S)

Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5G 1X5, Canada.

Jonah Beenstock (J)

Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5G 1X5, Canada.

Derek F Ceccarelli (DF)

Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5G 1X5, Canada.

Igor Kurinov (I)

Department of Chemistry and Chemical Biology, Cornell University, NE-CAT, Argonne, IL 60439, USA.

Gerald Gish (G)

Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5G 1X5, Canada.

Frank Sicheri (F)

Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5G 1X5, Canada; Department of Molecular Genetics, University of Toronto, ON M5S 1A8, Canada; Department of Biochemistry, University of Toronto, ON M5S 1A8, Canada. Electronic address: sicheri@lunenfeld.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH